Embecta Corp.

Embecta reported Q3 fiscal 2026 revenue of approximately $272 million, down 8.1% year over year as reported and down 8.9% on an adjusted constant-currency basis. GAAP gross profit was $153.3 million with a 56.4% margin, versus $197.1 million and 66.7% a year ago; adjusted gross profit was $158 million with a 58.2% margin, versus $198.6 million and 67.2%. GAAP operating income was $48.7 million with a 17.9% margin, versus $94 million and 31.8%; adjusted operating income was $69.4 million with a 25.5% margin, versus $109.1 million and 36.9%. GAAP EPS was $0.36 versus $0.78 last year, and adjusted EPS was $0.56 versus $1.12. Management reaffirmed full-year revenue guidance of $1.015 billion to $1.035 billion, raised adjusted operating margin guidance to 23.5% to 24% from 22.25% to 23.25%, and raised adjusted EPS guidance to $1.80 to $1.90 from $1.55 to $1.75. It also expects to repay at least $150 million of debt in 2026 and still expects about $100 million of free cash flow, including $18 million to $20 million of capex.

Dev Kurdikar emphasized that the quarter showed sequential recovery in the U.S. business, continued strength internationally, and an initial contribution from Owen Mumford. He framed the acquisition as a strategic expansion beyond insulin injection devices into pharma services and auto-injectors, highlighting a $2.4 billion auto-injector TAM and saying the company is now serving a broader customer base. His tone was constructive but measured: he repeatedly said the business is tracking within expectations and that management wants more time before giving detailed revenue expectations for new programs like Aidaptus.

Jake Elguicze focused on the margin and cash flow improvement embedded in the updated guidance. He cited Q3 adjusted gross profit of $158 million, adjusted gross margin of 58.2%, adjusted operating income of $69.4 million, and adjusted EPS of $0.56, then explained the year-over-year pressure came mainly from lower U.S. revenue and profit/inventory adjustments, partially offset by Owen Mumford and International. On the balance sheet, he said the company generated about $41 million of free cash flow, repaid about $53 million of debt, ended with last-12-month net leverage of about 3.7x versus a 4.75x covenant, and amended and extended the revolver through December 30, 2028. He also said capital allocation will remain primarily focused on continued debt reduction.

Analysts pressed management on competitive share loss from low-cost players, weaker U.S. insulin prescription trends, and whether the quarter signaled a change in demand. Dev said share was stable within the range of expectations, that market-appropriate syringes and pen needles should help offset low-cost competition over time, and that the U.S. guide assumes no further recovery or deterioration in prescription trends. On guidance, management said the reiterated revenue range reflects a desire to stay within the prior 90-day framework despite a Q3 beat, while cost controls and optimization justified higher margin and EPS targets. They also declined to quantify 2027 revenue growth or Aidaptus revenue timing, saying they want more operating history and program progress before updating long-range plans.